Vesugen
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Vesugen is a synthetic tripeptide made of three amino acids — lysine, glutamic acid, and aspartic acid — often abbreviated by its sequence, KED. It belongs to the family of short peptide bioregulators developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology, where each peptide is proposed to have a tissue-specific focus. For Vesugen, that focus is the vascular system.
Vesugen is commonly discussed in the context of vascular aging. It is studied for a proposed role in supporting the endothelium — the thin layer of cells lining blood vessels — and in maintaining healthy circulation as the cardiovascular system ages.
The evidence base is limited and comes predominantly from Russian preclinical work and small, often uncontrolled, clinical observations. Large placebo-controlled trials have not been published, and Vesugen is not approved by major regulators for therapeutic use.
How it works
Peptide bioregulators like Vesugen are proposed to act as signaling molecules that influence gene expression in a tissue-specific way. In the case of KED, preclinical research has focused on vascular endothelial cells, where the peptide has been reported to affect cell proliferation and markers associated with endothelial function.
Researchers have also described effects on cellular activity in neuroimmunoendocrine tissue cultures. The precise mechanism in humans is not established, and the epigenetic-signaling model remains a working hypothesis rather than a settled explanation.
Reported benefits
- Support for endothelial health and vascular function (preclinical and small clinical data)
- Improved arterial blood flow in studies of age-related vascular insufficiency
- Interest as part of broader anti-aging bioregulator protocols
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous, independently replicated human trials are lacking, the safety profile of Vesugen is not well characterized. The available studies have generally reported it to be well tolerated, but these were small and not designed to detect uncommon or long-term risks.
Product purity varies widely in the research-chemical market, and Vesugen is not a substitute for evaluation and treatment by a qualified clinician. Anyone with cardiovascular disease should discuss vascular health with a healthcare professional.
Frequently asked
What is Vesugen?
A synthetic tripeptide with the sequence Lys-Glu-Asp (KED), developed within the Khavinson family of peptide bioregulators and studied for its proposed effects on the vascular system.
Is Vesugen FDA-approved?
No. Vesugen is not approved by the FDA or any major Western regulator for human therapeutic use, and is sold for research purposes only.
What is Vesugen studied for?
It has been studied primarily in Russian preclinical and small clinical research for endothelial health, vascular function, and cardiovascular aging.
How strong is the evidence behind Vesugen?
Limited. Most published data comes from cell-culture, animal, and small uncontrolled human studies, largely from a single research group, without independent Western replication.
References
- Kitachev KV, et al. Efficacy of peptide bioregulators of vessels in lower-limb chronic arterial insufficiency in elderly people. ↗
- Chalisova NI, et al. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. ↗
- Meshchaninov VN, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity. ↗
Related compounds
AEDR tetrapeptide cardiovascular bioregulator. Supports cardiac gene regulation and cardiomyocyte metabolism. Studied for heart health and cardiovascular aging.
An oral Khavinson peptide bioregulator (peptide complex A-3) targeting blood vessels and vascular tissue. Taken in capsule courses to support cardiovascular and blood-vessel health.
An oral Khavinson peptide bioregulator (peptide complex A-8) targeting the pineal gland — the oral-capsule analog to the injectable Epithalon lineage. The most-studied compound in the Khavinson framework, tied to melatonin, circadian rhythm, and anti-aging research.